Concepedia

Author

Pascal Lenain

Centre Henri Becquerel

Also Known As

Laurent Garderet, Lenain, P., Lenain, Pascal, P Lenain, P. Lenain, Pascal LENAIN, Pascal Lenain, Philippe Rousselot

148

Publications

4.7K

Citations

28

H-Index

59

Concepts

All Affiliations

Centre Henri BecquerelInsermCentre Virchow-VillerméSorbonne UniversitéInstitut Paoli-Calmettes
PL

About

Pascal Lenain is an author at Centre Henri Becquerel specializing in medicine, hematology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

20

1.7K

2

Health Sciences

10

10

1.2K

3

Engineering

1

1

99

4

Public Health

1

1

16

5

Blood Transplantation

1

1

26

Pascal Lenain

×

50

Publications

4.4K

Citations

27

H-Index

YearCitations

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin,

The Lancet

2019

922

Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial

Jean‐Luc Harousseau, Michel Attal, Hervé Avet‐Loiseau,

Journal of Clinical Oncology

2010

528

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

Cyrille Hulin, Thierry Façon, Philippe Rodon,

Journal of Clinical Oncology

2009

380

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

Philippe Moreau, Hervé Avet‐Loiseau, Thierry Façon,

Blood

2011

302

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Philippe Moreau, Cyrille Hulin, Margaret Macro,

Blood

2016

273

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myélome (IFM)

Murielle Roussel, Philippe Moreau, Anne Huynh,

Blood

2009

171

patients with the description of a new scoring system and its validation on 253 other patients.

Pierre Morel, M. Monconduit, Dominique Jacomy,

PubMed

2000

134

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

Hervé Avet‐Loiseau, Florent Malard, L. Campion,

Blood

2010

126

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

Franck E. Nicolini, Stéphanie Dulucq, Lisa Boureau,

Clinical Cancer Research

2019

108

Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU

Bouchra Lamia, M.-F. Hellot, Christophe Girault,

Intensive Care Medicine

2006

105

Page 1